25781-99-1

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-Hydroxy-ethoxy)-benzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to their overall efficacy and stability.
Used in Cosmetic and Personal Care Industry:
3-(2-Hydroxy-ethoxy)-benzoic acid is used as a formulation aid for its ability to stabilize emulsions and enhance the solubility of other ingredients, improving the performance and quality of cosmetic and personal care products.
Used in Specialty Chemicals Production:
3-(2-Hydroxy-ethoxy)-benzoic acid is used as a building block in the production of dyes, fragrances, and other specialty chemicals due to its aromatic and hydrophilic properties, which allow it to be versatile and compatible with a wide range of other materials.

InChI:InChI=1/C9H10O4/c10-4-5-13-8-3-1-2-7(6-8)9(11)12/h1-3,6,10H,4-5H2,(H,11,12)

Upstream product

• 124-38-9 carbon dioxide 
• 6161-83-7 2-(3-chlorophenoxy)ethanol 
• 42772-85-0 2-hydroxyethyl 4-methylbenzenesulfonate 
• 99-06-9 3-Carboxyphenol 

Relevant academic research and scientific papers

Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy

Overexpression of protein tyrosine phosphatase 1B (PTP1B) induces insulin resistance in various basic and clinical research. In our previous work, a synthetic oleanolic acid (OA) derivative C10a with PTP1B inhibitory activity has been reported. However, C10a has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of C10a to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds 15, 28 and 34 exhibited the most PTP1B enzymatic inhibitory potency. In the insulin-resistant human hepatoma HepG2 cells, compound 25 with the moderate PTP1B inhibition and preferable pharmaceutical properties can significantly increase insulin-stimulated glucose uptake and showed the insulin resistance ameliorating effect. Moreover, 25 showed the improved in vivo antihyperglycaemic potential in the nicotinamide–streptozotocin-induced T2D. Our study demonstrated that these tricyclic derivatives with improved molecular architectures and antihyperglycaemic activity could be developed in the treatment of T2D.

Synthesis of lithium ω-(m- and p-lithiophenoxy)alkoxides modified with magnesium 2-ethoxyethoxide. Crystal structures of bis[4-(2-hydroxyethoxy)phenyl]mercury and bis[4-(3-hydroxypropoxy)phenyl]mercury

m- and p-Chlorinated ω-phenoxyalcohols 1, were transformed into the corresponding lithium ω-(m- and p-lithiophenoxy)alkoxides 4, respectively, by successive deprotonation with n-butyllithium and subsequent chlorine-lithium exchange by lithium naphthalene radical anion in THF-methylcyclohexane. Lithium 2-(4-lithiophenoxy)ethoxide (4a′) was also prepared by bromine-lithium exchange of 2-(4-bromophenoxy)ethanol (2a′) with two equivalents of n-butyllithium. The organolithiums were modified with magnesium 2-ethoxyethoxide in order to avoid ortho-metallation of the above-mentioned substituted arenes. Subsequent reaction of these intermediates with the electrophiles carbon dioxide, benzophenone, benzonitrile and 0.5 equivalents of mercuric chloride yielded the expected m- and p-substituted (ω-hydroxyalkoxy)benzenes in yields ranging from 50 to 75%. The crystal structures of the organomercurials 8a′ and 8b′ have been determined and revealed the Hg atom to occupy a crystallographic center of symmetry in a linear C-Hg-C arrangement.